Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

- Ranexa Revenue Grows 15 Percent Quarter-over-Quarter -

PALO ALTO, Calif., July 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the second quarter ended June 30, 2008.

For the quarter ended June 30, 2008, the Company reported a net loss of $4.3 million, or $0.07 per share. This compares to a net loss of $31.9 million, or $0.53 per share, for the prior quarter ended March 31, 2008 and $57.6 million, or $0.97 per share, for the same quarter in 2007.

For the quarter ended June 30, 2008, the Company recorded total revenues of $51.6 million which consisted of $25.4 million of net product sales of Ranexa(R) (ranolazine extended-release tablets), $4.0 million of royalty revenue and $22.2 million of license, collaboration and other revenue. The $25.4 million of net product sales for sales of Ranexa represents an increase of 15 percent compared to the $22.0 million of net product sales recorded in the prior quarter ended March 31, 2008. The $4.0 million of royalty revenue includes $2.6 million of amortization of our $175.0 million upfront payment earned from an investment trust related to TPG-Axon Capital in exchange for rights to 50 percent of our royalty on North American sales of Lexiscan(TM) (regadenoson) injection and $1.3 million of Lexiscan(TM) royalty revenue. The $22.2 million of license, collaboration and other revenue includes $12.0 million relating to a milestone payment from Astellas Pharma US. Inc. (Astellas) associated with the U.S. Food and Drug Administration (FDA) approval for Lexiscan(TM) and $10.0 million relating to a milestone payment from TPG-Axon Capital associated with the commercial launch of Lexiscan(TM).

Costs and expenses were $56
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... US demand for specialty biocides is forecast to ... 2018. In volume terms, demand is projected to increase ... the same period. A strong rebound in construction expenditures ... and paint and coatings markets, while growth in consumer ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 ... chitosan are natural biopolymers available in abundance in ... easily available resources such as shells of crustaceans. ... is mainly due to the high percentage of ... finds application in various industries owing to its ...
(Date:9/22/2014)... Research and Markets has announced the addition ... Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The microcrystalline ...
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 ... (OTCBB:GNBT) today announced that it has entered into ... to which UHN,s Centre for Molecular Design and ... refinement project.  The goal of the project is ... the Company,s proprietary buccal insulin spray product, thereby ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4
... 28, 2011 Nature,s Bioceuticals, a wholly owned subsidiary ... billion market chronic obstructive pulmonary disease market (COPD) with ... This all natural, non-synthetic, medicine was developed for the ... which are Emphysema and Chronic Bronchitis. We believe that ...
... at the Georgia Institute of Technology have developed a ... a key ingredient found in many explosives. ... on paper or paper-like material using standard inkjet technology, ... to the presence of explosives, such as improvised explosive ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... to Halozyme,s clinical stage drug, pegylated rHuPH20 (PEGPH20). The ... on "Molecular Markers in Cancer", taking place October 27-29 ...
Cached Biology Technology:Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 2Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 3Low-cost paper-based wireless sensor could help detect explosive devices 2Low-cost paper-based wireless sensor could help detect explosive devices 3Low-cost paper-based wireless sensor could help detect explosive devices 4Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 2Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 3
(Date:9/22/2014)... in a plant,s biological clock one that modulates ... , Transcription factors, or genetic switches, drive gene expression ... light, rain, soil quality, or even animals grazing on ... one, called FBH1, that reacts to temperature tweaking ... keeping it on a consistent track. , "Temperature helps ...
(Date:9/22/2014)... 22, 2014)The Brain & Behavior Research Foundation ... NARSAD Young Investigator Grants valued at more ... world,s most promising young scientists. Recipients of ... research will seek to identify causes, improve ... disorders that affect one in four people, ...
(Date:9/22/2014)... Evacuations of 2,819 people have occurred in the wake ... near the Eldorado National Forest. The King Fire ... of the American River Canyon, Silver Creek Canyon, and ... Pines. The fire has crossed into Placer County and ... Eldorado National Forest. The anticipated spread is expected to ...
Breaking Biology News(10 mins):Genetic switch regulates a plant's internal clock based on temperature 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2
... allergies and asthma is reduced when they are exposed in ... researchers have discovered a reason why. Exposure of mice ... indoors and outdoors can reshape the community of microbes that ... gastrointestinal microbiome and also diminish immune system reactivity to ...
... December 14, 2013 The groundbreaking Intergovernmental Platform ... to develop a set of assessments on pollination ... aimed at providing policymakers with the tools to ... delegates from over 100 governments, scientific organizations, civil ...
... Polytechnic Institute of New York University (NYU-Poly) and the ... in their lab that is five times more efficient ... methodsreagent vectors. This novel complex is a peptide-polymer hybrid, ... used to carry DNA into cells. Results ...
Cached Biology News:Research shows how household dogs protect against asthma and infection 2Research shows how household dogs protect against asthma and infection 3Pollination, land degradation: Top priorities for assessment by new UN intergovernmental body 2Pollination, land degradation: Top priorities for assessment by new UN intergovernmental body 3Researchers engineer a hybrid 5 times more effective in delivering genetic material into cells 2
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
... Beacon 2000 Fluorescence Polarization System is ... and assay development. Standard Beacon 2000 ... System uses a quartz-halogen lamp that ... 360-700 nm. It accommodates all applications ...
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
Biology Products: